Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible treatment. Their decision is informed by a comprehensive molecular profile ...

Drs Kathy Miller and Sunil Badve discuss how HER2 testing has evolved over time as the need for that clinical testing has shifted, including assay limits, biology, and clinical impact.

Human epidermal growth factor receptor 2 (HER2)–positive (HER2+) breast cancers make up  15% to 20% of all breast tumors. In this subtype, the H | Cancer ...

Resistant cells demonstrated global decreases in DNA accessibility with localized opening at resistance-driving loci, ...

A vaccine targeting a part of breast cancer tumors kept cancer from returning. May 16, 2012— -- A vaccine may be able to keep an aggressive type of breast cancer from returning in women who have ...

The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or ...

This study investigates the potential of amygdalin, a natural compound found in almonds, peaches, and apples, as a therapeutic agent for HER2-positive breast cancer. HER2 (human epidermal growth ...

Breast cancer is a complex disease with many types. Understanding the specific type and classification of the breast cancer you have is crucial so that you can fully participate as an informed partner ...

HER2-positive breast cancer is driven by HER2 protein overexpression, historically linked to poor outcomes but now improved by targeted therapies. Treatment varies by stage, involving surgery, ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. HER2-low breast cancer really means that ...